Bluejay finishes SYMON-II enrolment, but cash runway ends as its 510(k) window closes

What Bluejay reported

On 13 November 2026, US diagnostics company Bluejay Diagnostics said it has completed enrolment in SYMON-II, the pivotal study for its Symphony IL-6 test for sepsis. The company is targeting a 510(k) submission in the first half of 2027. It also said it has secured a backup cartridge manufacturing site.

The same disclosure puts cash at $7.38 million, with a runway that extends only to the second quarter of 2027. The records do not give SYMON-II's sample size, endpoints or data timing, and they say nothing about how the company plans to fund operations beyond that point. Those details are not yet known from the material available.

Why the timeline and the runway collide

A 510(k) is a premarket notification in which a sponsor shows FDA that a device is substantially equivalent to a legally marketed one. Completing enrolment is a milestone, but it is not the end of the work. Data still have to be locked, analysed and written up into a submission, and FDA then reviews it.

Bluejay's stated filing window is H1 2027, and its stated cash runway reaches only Q2 2027. Both end at the same point in the calendar. Unless the company files early, FDA's review would likely run past the end of the funded period, and the records do not say how that gap will be closed. Whether the filing happens on schedule, and what FDA decides, are not known.

For partners, clinical sites and suppliers, the practical question is whether the programme is funded through submission and review. The enrolment news alone does not answer that.

The backup site is the operational detail to note

The secured backup cartridge site is a small item in the announcement, but it matters for a diagnostic. The cartridge is the consumable on which the test runs, so a single manufacturing source is a supply risk. A second site addresses that risk, though the records do not say whether it is qualified, what its capacity is, or how its use would be handled in the submission.

This echoes a theme elsewhere in the records. On 13 November Health Canada listed a Type II recall in which Boston Scientific is correcting the instructions for use for Vercise Clinician Programmers, covering IPG recharge intervals and battery longevity estimates. Separately, BfArM published a field safety notice from BD Switzerland Sarl on the BD Connecta infusion connector, with the defect, affected lots and required actions set out only in the manufacturer's attached advisory. Neither case involves Bluejay. Both show that manufacturing and labelling details continue to matter after a product reaches the market.

Funding pressure is not unique to Bluejay

Other sponsors in the same week show how widely cash positions vary against regulatory milestones. TuHURA Biosciences won FDA IND clearance for a Phase 1b study of its VISTA antibody TBS-2025 in relapsed or refractory mutant NPM1 acute myeloid leukaemia, while reporting $1.9 million in cash. Zentalis reported Q3 2026 results, said Part 2c enrolment for azenosertib completes in November, and put its cash runway into the first half of 2028. It also expects to seek FDA talks on accelerated approval after the DENALI readout in 1H 2027.

Oncolytics Biotech and Coherus Oncology agreed that Coherus will supply LOQTORZI for a planned US study of pelareorep in squamous cell anal carcinoma. That arrangement shows another way sponsors secure the inputs for a trial.

The records give no outcomes for any of these programmes, so they should be read as context, not as predictions.

What to watch

First, watch Bluejay's next financial disclosures for any change to the runway or the H1 2027 filing target. Second, watch for detail on the study results and on the backup site's role in the submission. Neither is in the current records.

Separately, FDA has issued draft guidance on early-phase IND protocols for solid tumours, covering first-in-human trials and products with limited human experience. It excludes haematologic malignancies, so it would not cover a study like TuHURA's AML trial. Comments are open until 11 January 2027. The guidance concerns oncology drug trials rather than diagnostics like Symphony, but it is the main open consultation for early-phase solid tumour sponsors.